BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9042263)

  • 1. Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer.
    Caruso ML; Valentini AM
    Anticancer Res; 1996; 16(6B):3813-8. PubMed ID: 9042263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma.
    Lazaris AC; Theodoropoulos GE; Anastassopoulos P; Nakopoulou L; Panoussopoulos D; Papadimitriou K
    Histol Histopathol; 1995 Jul; 10(3):661-8. PubMed ID: 7579815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices.
    Ioachim E; Charchanti A; Stavropoulos N; Athanassiou E; Bafa M; Agnantis NJ
    Anticancer Res; 2002; 22(6A):3383-8. PubMed ID: 12530091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
    Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma.
    Micozkadioğlu D; Unal M; Pata YS; Baştürk M; Cinel L
    Med Sci Monit; 2008 Jun; 14(6):CR299-304. PubMed ID: 18509272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
    Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
    Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
    Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
    Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
    Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
    Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis.
    Fernández Aceñero MJ; Farina González J; Arangoncillo Ballesteros P
    Gen Diagn Pathol; 1997 Jun; 142(5-6):289-96. PubMed ID: 9228251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater.
    Ajiki T; Kamigaki T; Hasegawa Y; Fujino Y; Suzuki Y; Takeyama Y; Ku Y; Kuroda Y
    Hepatogastroenterology; 2001; 48(41):1266-70. PubMed ID: 11677943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.